pp65-specific T cells - Miltenyi Biotec

Drug Profile

pp65-specific T cells - Miltenyi Biotec

Alternative Names: CMV-specific T-cells; IFN-gamma positive selected T-cells

Latest Information Update: 20 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Miltenyi Biotec GmbH; Samsung Medical Center
  • Developer Miltenyi Biotec GmbH
  • Class Cytomegalovirus vaccines; Immunotherapies; Peptide vaccines; T lymphocyte cell therapies
  • Mechanism of Action Cell replacements; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cytomegalovirus infections

Most Recent Events

  • 13 Jan 2015 Preclinical trials in Cytomegalovirus infections treatment in Singapore before January 2015 (IV)
  • 13 Jan 2015 Miltenyi Biotec plans a phase I/II trial for Cytomegalovirus infections in South Korea (NCT02346617)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top